<qa>  What is the interval from prior treatment to time of IMGN901 administration?7. In the absence of rapidly progressing disease and after discussion with the Principal Investigator PI, the interval from prior treatment to time of IMGN901 administration will be at least 2 weeks or at least 5 half-lives for cytotoxicnoncytotoxic agents. The half-life be based on published pharmacokinetic literature abstracts, manuscripts, investigator brochures, or drug-administration manuals and will be documented in the protocol eligibility document. 